

**Question for written answer E-005088/2021
to the Commission**

Rule 138

Joanna Kopcińska (ECR)

Subject: USA-EU and HERA

On 22 September of this year, we were informed of the US-EU Agenda for Beating the Global Pandemic: 'Vaccinating the World, Saving Lives Now, and Building Back Better Health Security'. According to the Commission's statement, collaboration in terms of global action should be based on five pillars. Pillar IV (achieving Global Health Security) mentions a venture in which the EU and the USA (HERA and the Department of Health and Human Services Biomedical Advanced Research and Development Authority – BARDA) will cooperate in line with our G7 commitment to expedite the development of new vaccines and make recommendations on enhancing the world's capacity to deliver these vaccines.

The proposal for a Council regulation on a framework of measures for ensuring the supply of crisis-relevant medical countermeasures in the event of a public health emergency at Union level (COM(2021)0577), in the entries on the expected result(s) and impact – Specific objective No 4, clarifies the provisions on international engagement and reinforcement for medical countermeasures access and development, as well as threat assessments, surveillance and capacity building.

In the Commission's opinion, do the actions taken not go beyond the discussions currently under way, specifically in the context of: 1. budget implications, 2. management structure, the HERA backbone, and 3. involvement of other leading European institutions in the action plan and the abovementioned agenda?